Zolgensma gene therapy for sma patients: long-term data
$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian
Novartis faces serious delays in registration of Zolgensma in Russia
Novartis Boosts Zolgensma Production Capacity After FDA Clearance
Test Achats porte plainte contre un médicament à 2 millions d'euros
Zolgensma: Progress Report on the World's Most Expensive Drug | The Smart Cube
Novartis releases long-term data for SMA gene therapy
AMM européenne pour Scemblix® (asciminib) de Novartis
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge
Zolgensma Launch “On Track,” but Significant Challenges Remain - Bionest
Novartis to Open New Trial of Zolgensma for Older SMA Patients
Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve | Fierce Pharma
Four Takeaways from the Zolgensma Pricing Storm
News Archive | Novartis
R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence
FDA Lifts Partial Clinical Hold on Novartis' Gene Therapy Trial for Spinal Muscular Atrophy | BioSpace
Path clears for Novartis's Zolgensma after FDA lifts longstanding hold
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor
Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma
Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA
Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR
